Specialty Drugs Offer “Reasonable” Value, Tufts Analysis Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The study is the first to systematically evaluate the additional health gains and costs associated with specialty drugs, the researchers note.
You may also be interested in...
Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
Tie Goes To The Nominee: Becerra Heads To Senate Floor
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: